ICT

EQS-News: Mumtalakat Launches New Digital Solutions Provider “ARRAY”

Retrieved on: 
星期三, 三月 13, 2024

Manama, Kingdom of Bahrain 12, March 2024: Bahrain Mumtalakat Holding Company ( Mumtalakat ), the sovereign wealth fund of the Kingdom of Bahrain, signed an agreement to launch ARRAY Innovation (ARRAY), a new digital solutions provider with the support of the Bahrain Economic Development Board (Bahrain EDB).

Key Points: 
  • Manama, Kingdom of Bahrain 12, March 2024: Bahrain Mumtalakat Holding Company ( Mumtalakat ), the sovereign wealth fund of the Kingdom of Bahrain, signed an agreement to launch ARRAY Innovation (ARRAY), a new digital solutions provider with the support of the Bahrain Economic Development Board (Bahrain EDB).
  • Attending the signing were His Excellency Shaikh Abdulla bin Khalifa Al Khalifa, Chief Executive Officer of Mumtalakat of Mumtalakat, and Alaa Saeed, Co-Founder of ARRAY, a former Citi Managing Director and Crown Prince’s International Scholarship Program Alumni.
  • Bridging the gap between global digital innovation opportunities and local Bahraini talent, ARRAY will harness cutting-edge technologies integrating generative AI and Cloud capabilities to deliver premium digital solutions including consultancy services, professional and managed IT services, and turnkey resourcing solutions to a diverse range of businesses in the Kingdom of Bahrain, the region and globally.
  • the Minister of Sustainable Development and Chief Executive of Bahrain Economic Development Board added.

RM plc: Extension and amendment of Banking facility

Retrieved on: 
星期三, 三月 13, 2024

RM plc, (“RM”, the “Company”), a leading global educational technology, digital learning and assessment solution provider, announces that it has reached agreement with its lenders to extend its current facility by a further year to the end of July 2026.

Key Points: 
  • RM plc, (“RM”, the “Company”), a leading global educational technology, digital learning and assessment solution provider, announces that it has reached agreement with its lenders to extend its current facility by a further year to the end of July 2026.
  • All other requirements, including the fixed and floating charge and soft liquidity covenants, remain materially unchanged under the update.
  • "I am grateful for the continuing support of our lenders and the extension to our facility and amendment to the covenant tests.
  • RM is focused on delivering a consistently high-quality digital experience, acting as a trusted consultative partner to provide solutions that deliver real impact for learners worldwide.

Mumtalakat Launches New Digital Solutions Provider "ARRAY"

Retrieved on: 
星期二, 三月 12, 2024

Manama, Kingdom of Bahrain--(Newsfile Corp. - March 12, 2024) - Bahrain Mumtalakat Holding Company (Mumtalakat), the sovereign wealth fund of the Kingdom of Bahrain, signed an agreement to launch ARRAY Innovation (ARRAY), a new digital solutions provider with the support of the Bahrain Economic Development Board (Bahrain EDB).

Key Points: 
  • Attending the signing were His Excellency Shaikh Abdulla bin Khalifa Al Khalifa, Chief Executive Officer of Mumtalakat of Mumtalakat, and Alaa Saeed, Co-Founder of ARRAY, a former Citi Managing Director and Crown Prince's International Scholarship Program Alumni.
  • Bridging the gap between global digital innovation opportunities and local Bahraini talent, ARRAY will harness cutting-edge technologies integrating generative AI and Cloud capabilities to deliver premium digital solutions including consultancy services, professional and managed IT services, and turnkey resourcing solutions to a diverse range of businesses in the Kingdom of Bahrain, the region and globally.
  • ARRAY is committed to spearheading digital innovation, generating social impact, and enhancing Bahrain's position as a regional technology leader by providing specialised digital expertise to businesses and communities, fostering the development of local talent, and shaping a future where progress paves the way for positive change.
  • "ARRAY will provide at least 1,000 highly skilled jobs for Bahrainis, addressing the needs and serving a clientele of financial institutions, multinational corporations, and governments," H.E.

Transformative Power of Technology: Digital Transformation Summit 2024 Set to Redefine South Africa's Tech Landscape

Retrieved on: 
星期五, 三月 8, 2024

The much-anticipated Digital Transformation Summit is set to take place on March 15, 2024, at the prestigious Sandton Convention Centre.

Key Points: 
  • The much-anticipated Digital Transformation Summit is set to take place on March 15, 2024, at the prestigious Sandton Convention Centre.
  • The 27th Edition of the Digital Transformation Summit, South Africa, aims to delve deep into how organizations are embracing digital transformation, navigating challenges across various technologies, and bolstering cybersecurity measures.
  • Dr. Thabiso Njongwe, Chief Digital Transformation Officer, Absa Group, will discuss "Sustainable Digital Shift in South Africa: Challenges, Opportunities, and Inclusivity."
  • Join us at the Digital Transformation Summit South Africa on March 15th at the Sandton Convention Centre to be part of this transformative event.

NEC and Sumitomo Corporation Sign Strategic Partnership Agreement to Expand Global Sales of the CropScope Agricultural ICT Platform

Retrieved on: 
星期一, 三月 4, 2024

TOKYO, Mar 4, 2024 - (ACN Newswire) - NEC Corporation (TSE: 6701) and Sumitomo Corporation (Sumitomo) have signed a strategic partnership agreement to expand global sales of NEC's agricultural ICT platform CropScope.

Key Points: 
  • TOKYO, Mar 4, 2024 - (ACN Newswire) - NEC Corporation (TSE: 6701) and Sumitomo Corporation (Sumitomo) have signed a strategic partnership agreement to expand global sales of NEC's agricultural ICT platform CropScope.
  • Based on this partnership, NEC and Sumitomo aim to develop markets mainly in South America and the ASEAN region by utilizing Sumitomo's global network.
  • Through this partnership, CropScope is initially being introduced on a trial basis to major sugar companies in Thailand and Brazil.
  • Through this partnership, Sumitomo will utilize its global network to expand CropScope's sales area to Thailand, Brazil, and India, aiming for business growth.

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
星期一, 三月 11, 2024

WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.

Key Points: 
  • WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.
  • Research and development expenses were $40.5 million for the year ended December 31, 2023, compared to $62.5 million for 2022.
  • 2023 and Recent Corporate Highlights:
    In July 2023, Mustang announced that it amended its previously announced asset purchase agreement with uBriGene (Boston) Biosciences Inc. (“uBriGene”) and closed the transaction.
  • In October 2023, Mustang completed a registered direct offering priced at-the-market for approximately $4.4 million in gross proceeds.

EXL Announces Appointment of Thomas Bartlett to Board of Directors and Retirement of Board Member Som Mittal

Retrieved on: 
星期四, 三月 7, 2024

The company also announced that Som Mittal has notified the board that he will not stand for re-election at EXL’s 2024 annual meeting of stockholders and therefore will be retiring from the board in June 2024.

Key Points: 
  • The company also announced that Som Mittal has notified the board that he will not stand for re-election at EXL’s 2024 annual meeting of stockholders and therefore will be retiring from the board in June 2024.
  • “We are excited to welcome Tom to the board,” said Board Chair Vikram Pandit.
  • “On behalf of EXL and its board of directors, I would also like to thank Som for the wisdom and insights he has contributed since joining the board in 2013,” said Pandit.
  • “EXL is well positioned to take advantage of the coming AI economy, and I look forward to following its continued success.”

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Retrieved on: 
星期四, 三月 7, 2024

WORCESTER, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced Phase 1 clinical data were published in Nature Medicine that demonstrated the promising safety and clinical activity of Mustang’s MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of patients with recurrent and refractory malignant glioma, including glioblastoma.

Key Points: 
  • MB-101 was developed by City of Hope, one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Mustang.
  • Central nervous system (CNS) increases in inflammatory cytokines, including IFNγ, CXCL9, and CXCL10, were associated with CAR T-cell administration and bioactivity.
  • Primary endpoints were safety and feasibility, with secondary endpoints measuring therapy-related cytokine dynamics, CAR T-cell persistence and clinical outcomes.
  • Dr. Brown has a financial interest in Mustang and has previously been a paid consultant for the company.

SYLA Technologies Subsidiary SYLA Solar Announces Comprehensive Business Alliance with LIVE THE CREATIVE

Retrieved on: 
星期一, 三月 4, 2024

TOKYO, March 04, 2024 (GLOBE NEWSWIRE) -- SYLA Technologies Co., Ltd. (NASDAQ: SYT) (“SYLA” or “the Company”), operator of the largest membership real estate crowd-funding platform in Japan, Rimawari-kun, announced its subsidiary, SYLA Solar Co., Ltd. (“SYLA Solar”) has entered into a Comprehensive Business Alliance Agreement with LIVE THE CREATIVE Inc. (“LIVE THE CREATIVE”) to innovate solar power plant development.

Key Points: 
  • TOKYO, March 04, 2024 (GLOBE NEWSWIRE) -- SYLA Technologies Co., Ltd. (NASDAQ: SYT) (“SYLA” or “the Company”), operator of the largest membership real estate crowd-funding platform in Japan, Rimawari-kun, announced its subsidiary, SYLA Solar Co., Ltd. (“SYLA Solar”) has entered into a Comprehensive Business Alliance Agreement with LIVE THE CREATIVE Inc. (“LIVE THE CREATIVE”) to innovate solar power plant development.
  • The business alliance between SYLA Solar and LIVE THE CREATIVE combines the expertise and advanced technologies of both companies to synergistically innovate solar power plant development.
  • SYLA Solar brings its extensive knowledge spanning from land acquisition to regulatory compliance and design within solar power plant development.
  • Meanwhile, LIVE THE CREATIVE delivers highly precise and efficient surveying solutions utilizing drone technology.

Draft guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations

Retrieved on: 
星期二, 三月 12, 2024

16

Key Points: 
    • 16

      Guideline on allergen products development for
      immunotherapy and allergy diagnosis in moderate to lowsized study populations

      17

      Table of contents

      18

      Executive summary ..................................................................................... 3

      19

      1.

    • Specific effects ................................................................................................. 17

      14
      15

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 2/18

      53

      12.

    • Management for allergies may involve avoidance of the allergen, medications to relieve

      66

      symptoms, or allergen immunotherapy (AIT) to desensitize the immune system to the allergen.

    • 71

      Recommendations are made on the clinical development, potential study designs and safety

      72

      considerations for allergen products within the scope of the guideline.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 3/18

      88

      While allergen specific immunotherapy is the only known disease modifying therapy for type I allergies,

      89

      there is no such treatment available for type IV allergies.

    • 93

      Several guidelines applicable for allergen products are available (see section 3) and provide advice on

      94

      quality and clinical development according to the current knowledge.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 4/18

      127

      However, this guideline does not cover the indication of atopic dermatitis or asthma as these

      128

      conditions will require separate clinical trials (see Section 6).

    • 129

      In addition, the guideline does not cover medicinal allergen products manufactured using recombinant

      130

      DNA technology, synthetic peptides, DNA or RNA constructs and/or cell preparations as they differ

      131

      substantially to the allergen products as discussed above.

    • 1

      156

      ?

      Guideline on the clinical development of products for specific immunotherapy for the treatment

      157
      158

      of allergic diseases - CHMP/EWP/18504/2006
      ?

      159
      160
      161

      Guideline on Allergen Products: Production and Quality Issues EMEA/CHMP/BWP/304831/2007

      ?

      Guideline on process validation for finished products - information and data to be provided in
      regulatory submissions - EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1, Corr.1

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 5/18

      162

      ?

      Recommendations on common regulatory approaches for allergen products - CMDh/399/2019

      163

      4.

    • In any

      199

      case, a reduced validation should include all relevant manufacturing process steps that are considered
      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 6/18

      200

      product specific.

    • 290

      Diagnostic allergen products (Type I allergy)

      291

      A possible target indication is diagnosis of type I hypersensitivity (immediate-type allergy) by prick,

      292

      intracutaneous or provocation testing.

    • 298

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 9/18

      305
      306

      7.1.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 11/18

      377

      8.

    • Clinical development of products for AIT: Study design,
      efficacy and safety

      378

      In general, the clinical development should be performed according to current guidelines.

    • In such single trial, the suitability as a test allergen as well as the

      376

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 12/18

      415

      dose finding for the therapeutic allergen could be investigated.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 13/18

      454
      455

      8.2.1.

    • 493

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 15/18

      527

      In general, sensitivity and specificity of the product should be determined.

    • 540

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 16/18

      561

      10.2.

    • Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 17/18

      595

      4.

    • Allergol Immunopathol, 1989;

      602

      17(2):53-65

      603

      Guideline on allergen products development for immunotherapy and allergy diagnosis
      in moderate to low-sized study populations
      EMA/CHMP/72790/2024

      Page 18/18